CN112220759A - 一种抗菌水凝胶载药微球的制备及其在细胞扩增中的应用 - Google Patents
一种抗菌水凝胶载药微球的制备及其在细胞扩增中的应用 Download PDFInfo
- Publication number
- CN112220759A CN112220759A CN202011111444.4A CN202011111444A CN112220759A CN 112220759 A CN112220759 A CN 112220759A CN 202011111444 A CN202011111444 A CN 202011111444A CN 112220759 A CN112220759 A CN 112220759A
- Authority
- CN
- China
- Prior art keywords
- hydrogel
- microspheres
- drug
- antibacterial
- loaded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 99
- 239000000017 hydrogel Substances 0.000 title claims abstract description 94
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 229940079593 drug Drugs 0.000 title claims abstract description 51
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 230000003321 amplification Effects 0.000 title claims abstract description 7
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 27
- 210000004027 cell Anatomy 0.000 claims abstract description 21
- 239000004038 photonic crystal Substances 0.000 claims abstract description 19
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000011068 loading method Methods 0.000 claims abstract description 7
- 238000001704 evaporation Methods 0.000 claims abstract description 6
- 238000003837 high-temperature calcination Methods 0.000 claims abstract description 6
- 210000002865 immune cell Anatomy 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 230000003213 activating effect Effects 0.000 claims abstract description 5
- 230000001363 autoimmune Effects 0.000 claims abstract description 5
- 238000005530 etching Methods 0.000 claims abstract description 3
- 238000011049 filling Methods 0.000 claims abstract description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 57
- 239000000377 silicon dioxide Substances 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 22
- 235000012239 silicon dioxide Nutrition 0.000 claims description 22
- 239000011022 opal Substances 0.000 claims description 10
- 229920001661 Chitosan Polymers 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 229920002545 silicone oil Polymers 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 230000002572 peristaltic effect Effects 0.000 claims description 3
- 229910052710 silicon Inorganic materials 0.000 claims description 3
- 239000010703 silicon Substances 0.000 claims description 3
- 239000003292 glue Substances 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 229940125644 antibody drug Drugs 0.000 claims 2
- 230000008020 evaporation Effects 0.000 abstract description 2
- 230000004936 stimulating effect Effects 0.000 abstract description 2
- 239000000499 gel Substances 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 230000005909 tumor killing Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011111444.4A CN112220759A (zh) | 2020-10-16 | 2020-10-16 | 一种抗菌水凝胶载药微球的制备及其在细胞扩增中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011111444.4A CN112220759A (zh) | 2020-10-16 | 2020-10-16 | 一种抗菌水凝胶载药微球的制备及其在细胞扩增中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112220759A true CN112220759A (zh) | 2021-01-15 |
Family
ID=74117774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011111444.4A Pending CN112220759A (zh) | 2020-10-16 | 2020-10-16 | 一种抗菌水凝胶载药微球的制备及其在细胞扩增中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112220759A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113244178A (zh) * | 2021-06-04 | 2021-08-13 | 南京鼓楼医院 | 一种远程可控药物释放的结冷胶复合载药微球及其制备方法和应用 |
CN115845811A (zh) * | 2022-12-07 | 2023-03-28 | 中山大学附属第八医院(深圳福田) | 一种用于检测六价铬离子的壳聚糖光子晶体微球及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110496104A (zh) * | 2019-09-27 | 2019-11-26 | 兆科(广州)肿瘤药物有限公司 | 一种载有ICIs单抗的载药微球及其制备方法 |
CN110755408A (zh) * | 2019-09-23 | 2020-02-07 | 中国人民解放军东部战区总医院 | 一种可缓释生长因子的壳聚糖抗菌微球及其制备方法和应用 |
CN111265492A (zh) * | 2020-04-17 | 2020-06-12 | 南京鼓楼医院 | 一种具有润滑作用的温度响应性载药微球及其制备方法 |
CN111407739A (zh) * | 2020-04-17 | 2020-07-14 | 南京鼓楼医院 | 一种具有肿瘤微环境响应性的载药微球制备方法 |
-
2020
- 2020-10-16 CN CN202011111444.4A patent/CN112220759A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110755408A (zh) * | 2019-09-23 | 2020-02-07 | 中国人民解放军东部战区总医院 | 一种可缓释生长因子的壳聚糖抗菌微球及其制备方法和应用 |
CN110496104A (zh) * | 2019-09-27 | 2019-11-26 | 兆科(广州)肿瘤药物有限公司 | 一种载有ICIs单抗的载药微球及其制备方法 |
CN111265492A (zh) * | 2020-04-17 | 2020-06-12 | 南京鼓楼医院 | 一种具有润滑作用的温度响应性载药微球及其制备方法 |
CN111407739A (zh) * | 2020-04-17 | 2020-07-14 | 南京鼓楼医院 | 一种具有肿瘤微环境响应性的载药微球制备方法 |
Non-Patent Citations (1)
Title |
---|
葛金龙: "《金属有机框架材料制备及其应用》", 30 September 2019 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113244178A (zh) * | 2021-06-04 | 2021-08-13 | 南京鼓楼医院 | 一种远程可控药物释放的结冷胶复合载药微球及其制备方法和应用 |
CN113244178B (zh) * | 2021-06-04 | 2022-05-31 | 南京鼓楼医院 | 一种远程可控药物释放的结冷胶复合载药微球及其制备方法和应用 |
CN115845811A (zh) * | 2022-12-07 | 2023-03-28 | 中山大学附属第八医院(深圳福田) | 一种用于检测六价铬离子的壳聚糖光子晶体微球及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nooshabadi et al. | Impact of exosome‐loaded chitosan hydrogel in wound repair and layered dermal reconstitution in mice animal model | |
CN112107547A (zh) | 一种具有光热响应性的水凝胶微球及其制备方法和应用 | |
CN112220759A (zh) | 一种抗菌水凝胶载药微球的制备及其在细胞扩增中的应用 | |
CN1325271A (zh) | 能快速生长并产生增殖抑制性物质的受限细胞的组合物及其用途 | |
CN113940949B (zh) | 一种负载外泌体的GelMA水凝胶微针及其制备方法和应用 | |
CN112592894B (zh) | 一种光热驱动药物释放水凝胶微球的制备方法及应用 | |
WO2016140716A1 (en) | Injectable microtissue systems, devices, and methods | |
CN1769430A (zh) | 含有抑制癌细胞增殖的因子的条件培养基及其制备方法 | |
CN106215171A (zh) | 一种间充质干细胞注射液及其制备方法和应用 | |
CN1296477C (zh) | 含有抑制癌细胞增殖的因子的条件培养基及其制备方法 | |
KR100675459B1 (ko) | 다관능 생체적합 친수성 젤 및 그 제조방법 | |
US10928383B2 (en) | Method for predicting effect of drug | |
CN112592895B (zh) | 一种激活性抗体修饰光子晶体水凝胶杂化载药微球的制备方法及应用 | |
CN109749999A (zh) | 肿瘤体外培养方法及临床化疗药物筛选方法 | |
CN110755607B (zh) | 氧化锌、抗原共载药物纳米疫苗、其制备方法与应用 | |
WO2019237771A1 (zh) | 一种治疗脑部疾病的干细胞制剂海绵贴片复合体、其制备方法及应用 | |
CN115998945A (zh) | 搭载药物控释微球的多功能水凝胶补片的制备方法与应用 | |
CN109260228A (zh) | 一种治疗肿瘤的复合物 | |
Winn et al. | Hydrogel applications for encapsulated cellular transplants | |
CN112220758A (zh) | 一种具有光热响应性的可融化水凝胶载药微球的制备及其在细胞扩增中的应用 | |
CN108085294A (zh) | 复合细胞的三维类组织体及其制备方法和应用 | |
CN106491630A (zh) | 一个新的靶向肝癌干细胞的miRNA的检测及应用 | |
CN113584012B (zh) | 一种ga-t细胞及其制备方法以及在白血病和抗gvhd中的应用 | |
Luo et al. | A poly (glycerol-sebacate-acrylate) nanosphere enhanced injectable hydrogel for wound treatment | |
CN109010914A (zh) | 一种应用于铁超载区域的干细胞支架及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Shen Xian Inventor after: Shou Xin Inventor after: Zhao Yuanjin Inventor after: Shang Liran Inventor after: Wang Yuetong Inventor after: Sun Weijian Inventor before: Shen Xian Inventor before: Shou Xin Inventor before: Zhao Yuanjin Inventor before: Shang Liran Inventor before: Wang Yuetong Inventor before: Sun Weijian |
|
CB03 | Change of inventor or designer information | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210115 |
|
RJ01 | Rejection of invention patent application after publication |